Aobo Capital
奥博资本
Aobo Capital is the Chinese name for OrbiMed, a healthcare-focused investment firm described by 5Y Capital as an "internationally renowned healthcare investor" . In elsewhere's corpus it shows up repeatedly on the medical side of deal announcements: it led Minghui Pharmaceutical's $131 million pre-IPO round in August 2025 , led Zhitai Bio's RMB 500 million-plus Series C , and has been a repeat Pulnovo Medical backer — joining its 2022 round , doubling down in the near-$100 million Series C in early 2025 , and following on again in the $100 million Series D in 2026 . It's also an existing shareholder in Jieti Medical . Elsewhere's corpus doesn't carry a fuller profile of the firm itself — founding details, AUM, or team — beyond these portfolio appearances.
AI-generated — may contain errors, please verify.
Coverage
Pulnovo Medical Completes $100 Million Series D Round Led by Medtronic, with Gaorong Ventures Continuing to Invest
Medtronic and Pulnovo Medical have signed a commercial cooperation agreement.
Jieti Medical Closes 500 Million Yuan Strategic Round; Source Code Capital Co-Led Previous Round
Source Code Capital continued to follow on in this round as an existing shareholder. In the previous round, Source Code Capital was a co-lead investor.
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
Pulnovo Medical closes nearly $100 million Series C, setting a new Asia-Pacific record for medical device financing
A pioneer in China's original medical device innovation.
Morning Star | Pulnovo Medical Raises Nearly $100 Million in Series C, Co-Led by Qiming Venture Partners | Bilingual
This round was oversubscribed twice, making it the largest market-driven financing in the Asia-Pacific innovative medical device sector in recent years.
Pulnovo Medical Closes New Tens-of-Millions USD Funding Round to Accelerate Global Expansion
It secured a foothold in global markets and made substantial headway on multiple fronts in 2022.
The Gambler's Mirage in a Downturn: When a Fund Goes All-In on a Single Company
In the investment industry, it's as ubiquitous as air. When markets plunge, it also faces the greatest risk.
